Extent of disease in recurrent prostate cancer determined by [68Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score

Abstract

[(68)Ga]PSMA-HBED-CC PET/CT will identify PCA lesions even in patients with very low PSA levels. Higher PSA levels and shorter PSAdt are independently associated with scan positivity and extrapelvic metastases, and can be used for patient selection for [(68)Ga]PSMA-HBED-CC PET/CT.

Molecular imaging using PSMA PET/CT versus multiparametric MRI for initial staging of prostate cancer: comparing apples with oranges?

“…Wherever local laws and regulations allow and a sufficiently equipped radiochemical laboratory is available, this tracer has now completely replaced radiolabelled choline PET/CT in the imaging of recurrent PCA. Indeed, even though the first results from larger retrospective series have only been published in the last 18 months [2][3][4][5] This molecular imaging approach certainly represents a major advance over previous PET/CT tracers. It has a much better signal-to-background ratio and its very strong uptake in target lesions allows lesions as small as 2.4 mm in short-axis diameter to be detected [6].…”

Surface-enhanced Raman spectroscopy of serum accurately detects prostate cancer in patients with prostate-specific antigen levels of 4–10 ng/mL

“…16 Serum metabolites showed promising capacity of analyzing molecular composition, however, they are an expensive and complex technology, which may introduce challenges for clinical application. 17 Numerous methods and techniques have been applied in PCa detection, such as computed tomography (CT)/positron emission tomography (PET) by 18 F-choline 18 and gallium-68 PSMA ligand Glu-urea-Lys(Ahx)-HBED-CC, 19 biopsy 20 and PSA screen. 21 However, it is difficult for CT to detect PCa in early stage.…”

Seduction by Sensitivity: Reality, Illusion, or Delusion? The Challenge of Assessing Outcomes after PSMA Imaging Selection of Patients for Treatment

“…Although this might influence the likelihood of response, it might also indicate a more indolent disease process in which an observational strategy may limit side effects without adversely affecting survival. Consistent with this hypothesis, PSA doubling time has also been shown to be a predictive factor for a positive PSMA PET/CT (27,28). An exception to the general rule that a negative scan implies either small volume or low-grade prostate cancer is the observation that neuroendocrine differentiation can be associated with low PSMA expression (29), and yet this is known to be an adverse prognostic group and can have low PSA levels (30).…”